- NASDAQ:BNGO surges by 23.45% after regaining NASDAQ compliance.
- BNGO’s Saphyr platform shines at the annual Next-Generation Cytogenics Symposium.
- BNGO has the attention of noted investment firm Ark invest.
NASDAQ:BNGO continued its 2021 momentum as the red-hot genomics sector keeps hitting new highs on a daily basis. On Thursday, small-cap upstart BioNano Genomics caught the eye of value investors as the stock added 23.45% to close the trading session at $6.95, but not before hitting new 52-week highs of $7.95 during intraday hours. Shares are up over 150% already this year and as the COVID-19 pandemic continues to hit our world hard, healthcare and biogenomics are at the forefront of investor interest.
That interest was clear as BioNano Genomics presented its Saphyr platform at the Next-Generaton Cytogenics Symposium this year and impressed medical professionals with its accuracy in detecting tumors, as well as saving doctors time and money without having to run extra costly tests or scans. BNGO also announced that it would be revealing information on how Saphyr can detect genetic drivers that lead to increased susceptibility to COVID-19. The Saphyr platform is able to identify structural variants in our genes that have control over potential immune system responses. The importance of this? Determining why some people react severely to COVID-19, while some remain symptomatic.
BNGO stock price
If all of that is not enough for investors, noted genomics industry investors ARK invest have also apparently been keen to know more about BNGO. ARK investor Simon Barnett was reported to be interested in speaking with BNGO’s CEO Dr. Robert Erik Holmlin late in 2020, so investors are anticipating that BNGO could be added to ARK’s genomics ETF ARK.G at some point in the near future, especially after its impressive showing at the symposium.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.
Latest Forex News
Editors’ Picks
EUR/USD failed to recover above 1.2100
The shared currency remains under selling pressure against its American rival, trading in the 1.2080 area. Market players waiting for more hints in the form of April Retail Sales.
GBP/USD under pressure below 1.4050 amid renewed USD demand
GBP/USD trades pressured below 1.4050, as the US dollar remains broadly bid amid risk-off sentiment. Rising inflationary pressures and Brexit jitters over NI keep investors on the edge. Bailey's speech, US data in focus.
XAU/USD respects the 10-day EMA
Gold could be on the verge of a lower low, but the hourly time frame is key. The hourly support structure is guarding a break to test bullish commitments at 1,800. The 10-day EMA and confluence of the 50% mean reversion are also offering support. Gold Weekly Forecast: XAU/USD could target 200-day SMA
Yearn Finance Price Forecast: YFI eyes consolidation after quick surge
Yearn Finance price tagged the channel’s upper trend line yesterday, falling just short of $100,000 and 261.8% Fibonacci extension target at $102,900. The sharp reversal from the trend line marks a significant turning point for YFI that will shift price action to consolidation from the uptrend beginning at the April 25 low.
US markets lead the recovery as jobless claims decline
Ongoing inflation fears remain, yet improved jobless claims help lift spirits in the US. Meanwhile, UK reopening stocks have been dealt a blow after SAGE claimed that a rise in the Indian Covid strain could slow the pace of lockdown easing.